Enanta Pharmaceuticals (NASDAQ:ENTA) Lifted to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a buy rating in a report issued on Saturday, Zacks.com reports. Zacks Investment Research currently has $82.00 price target on the biotechnology company’s stock.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Several other research analysts have also weighed in on the stock. Wolfe Research initiated coverage on shares of Enanta Pharmaceuticals in a report on Friday, May 24th. They set an outperform rating and a $117.00 price objective on the stock. BidaskClub lowered shares of Enanta Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, July 31st. Finally, Berenberg Bank upgraded shares of Enanta Pharmaceuticals from a hold rating to a buy rating and increased their price objective for the stock from $80.00 to $120.00 in a report on Tuesday, April 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $104.75.

Shares of ENTA stock opened at $73.14 on Friday. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 21.02 and a beta of 0.98. Enanta Pharmaceuticals has a 1-year low of $64.08 and a 1-year high of $106.80. The business’s 50-day moving average is $80.18.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.27. The business had revenue of $44.40 million for the quarter, compared to analyst estimates of $46.98 million. Enanta Pharmaceuticals had a net margin of 29.22% and a return on equity of 15.16%. The company’s revenue was down 22.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.97 EPS. On average, equities analysts expect that Enanta Pharmaceuticals will post 2.33 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in Enanta Pharmaceuticals by 1.5% in the second quarter. BlackRock Inc. now owns 2,592,357 shares of the biotechnology company’s stock valued at $218,743,000 after buying an additional 37,417 shares during the period. Janus Henderson Group PLC raised its holdings in Enanta Pharmaceuticals by 8.1% in the second quarter. Janus Henderson Group PLC now owns 944,787 shares of the biotechnology company’s stock valued at $79,721,000 after buying an additional 70,390 shares during the period. Acadian Asset Management LLC raised its holdings in Enanta Pharmaceuticals by 3.8% in the second quarter. Acadian Asset Management LLC now owns 405,269 shares of the biotechnology company’s stock valued at $34,196,000 after buying an additional 14,793 shares during the period. FMR LLC raised its holdings in Enanta Pharmaceuticals by 19.5% in the first quarter. FMR LLC now owns 240,195 shares of the biotechnology company’s stock valued at $22,944,000 after buying an additional 39,200 shares during the period. Finally, Northern Trust Corp raised its holdings in Enanta Pharmaceuticals by 1.1% in the second quarter. Northern Trust Corp now owns 234,037 shares of the biotechnology company’s stock valued at $19,749,000 after buying an additional 2,657 shares during the period. Hedge funds and other institutional investors own 90.22% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: Discount Rate

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.